EUVIMEDEUVIMED entdecken
Evaluationsstudie

Performance evaluation of the chemiluminescence immunoassay for quantitative detection of (1, 3)-β-D-glucan for diagnosis of invasive fungal diseases

Kaixuan Yuan iD, Ying Zhao, Long Ye, Suling Liu, Aiwei Huang, Zhuoxi Chen, Wenjuan Yan, Sisi Niu, Kexin Hua, Qing Wang, Ge Zhang, Ying-Chun Xu und 1 weitere

Medical Mycology · 2026

DOI: 10.1093/mmy/myag003 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Medical Mycology, 2026. Verfasst von Kaixuan Yuan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical Universi…. Hauptthemen laut MEDLINE: beta-Glucans, Invasive Fungal Infections, Luminescent Measurements. Die Arbeit nennt 33 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To assess the performance of a fully automated chemiluminescence immunoassay (CLIA) for the quantitative detection of (1, 3)-β-D-glucan (BDG) in serum samples for the diagnosis of invasive fungal diseases (IFD) and compare the results with the photometric assay, serum samples were collected from 604 patients with clinically suspected IFD between December 2022 and September 2023. According to the 2019 European Organization for Research and Treatment of Cancer and Mycoses Study Group guideline, patients were divided into the IFD group (comprising 43, 224, and 81 proven, probable, and possible cases, respectively) and the non-IFD group (256 cases), and BDG in serum samples was measured using both the CLIA and photometric assays. The sensitivity of the CLIA assay for invasive aspergillosis (IA), pneumocystis pneumonia (PCP), and invasive candidiasis (IC) was 88.66% (95% confidence interval [CI], 80.22–93.93%), 82.35% (95% CI, 55.80–92.18%) and 75.90% (95% CI, 68.54–82.04%), respectively, with a specificity of 97.27% (95% CI, 94.21–98.80%). The sensitivity of the photometric assay for IA, PCP, and IC was 89.69% (95% CI, 81.44–94.67%), 76.47% (95% CI, 49.76–92.18%), and 72.89% (95% CI, 65.35–79.35%), respectively, with a specificity of 100.00% (95% CI, 98.16–100.00%). The sensitivity of the CLIA assay was superior to that of the photometric assay (79.60% vs. 77.59%) in diagnosing proven/probable/possible IFD, but the specificity was lower than that of the photometric assay (97.27% vs. 100.00%). The performance of the CLIA assay was highly consistent with that of the photometric assay, both quantitatively (rs = 0.833) and qualitatively (kappa = 0.913). Lowering the cutoff value of the CLIA assay from 90.00 to 85.23 pg/ml improved diagnostic efficiency, with a sensitivity and specificity of 80.17% and 96.88%, respectively. Overall, the diagnostic performance of the two assays was comparable, with the CLIA assay having a higher sensitivity for the diagnosis of IFD. Considering the convenience of automated analysis and point-of-care testing, the CLIA assay is a promising alternative to conventional assays for diagnosing IFD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-GlucansInvasive Fungal InfectionsLuminescent MeasurementsHumansSensitivity and SpecificityImmunoassayProteoglycansFemaleMiddle AgedMaleAgedAdultCandidiasis, InvasivePneumonia, Pneumocystis

Stichwörter der Autor:innen

(13)-β-D-glucanchemiluminescence immunoassaydiagnosisinvasive fungal diseasesphotometric assay

Substanzen

beta-GlucansProteoglycanspolysaccharide-K

Autor:innen und Institutionen

  • Department of Clinical Laboratory Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong 510080, China.
  • Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, C…
  • Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.

ORCID-Profile: Kaixuan Yuan

Förderung

  • National High Level Hospital Clinical Research Funding

Zitieren

APA

Yuan, K., Zhao, Y., Ye, L., Liu, S., Huang, A., Chen, Z., Yan, W., Niu, S., Hua, K., Wang, Q., Zhang, G., Xu, Y. C., & Li, G. (2026). Performance evaluation of the chemiluminescence immunoassay for quantitative detection of (1, 3)-β-D-glucan for diagnosis of invasive fungal diseases. Medical Mycology. https://doi.org/10.1093/mmy/myag003

Vancouver

Yuan K, Zhao Y, Ye L, Liu S, Huang A, Chen Z, et al. Performance evaluation of the chemiluminescence immunoassay for quantitative detection of (1, 3)-β-D-glucan for diagnosis of invasive fungal diseases. Medical Mycology. 2026. doi:10.1093/mmy/myag003

BibTeX
@article{Yuan2026,
  author = {Yuan, Kaixuan and Zhao, Ying and Ye, Long and Liu, Suling and Huang, Aiwei and Chen, Zhuoxi and Yan, Wenjuan and Niu, Sisi and Hua, Kexin and Wang, Qing and Zhang, Ge and Xu, Ying-Chun and Li, Guanghua},
  title = {Performance evaluation of the chemiluminescence immunoassay for quantitative detection of (1, 3)-β-D-glucan for diagnosis of invasive fungal diseases},
  journal = {Medical Mycology},
  year = {2026},
  doi = {10.1093/mmy/myag003}
}
Kostenlos starten →